Venous Thromboembolism - Drug Pipeline Landscape, 2023

Venous Thromboembolism - Drug Pipeline Landscape, 2023

Venous thrombosis occurs due to the blockage of the veins caused by a thrombus (blood clot). A common form of venous thrombosis is deep vein thrombosis (DVT), this occurs when blood clots in the deep veins. If a blood clot breaks off (embolizes) and flows to the lungs to lodge, then it becomes a pulmonary embolism (PE). The conditions including DVT only, DVT with PE, and PE only altogether referred as "Venous Thromboembolism".

Venous thromboembolism is caused by a combination of venous stasis and hypercoagulability, and to a lesser extent endothelial damage and activation also plays a crucial role. The most common causes are injury and infections. In some cases, it might be due to medical intervention including surgery, chemotherapy, inserting IV or catheter.

Venous thromboembolism can be diagnosed by the initial screening through the signs and symptoms of the condition. DVT are diagnosed through blood tests, vascular ultrasound, MR venography and contrast venography. PE can be diagnosed through pulse oximetry, chest X-ray, CT pulmonary angiography and pulmonary angiogram.

Venous Thromboembolism is diagnosed through CT pulmonary angiography - also called CT pulmonary embolism which creates 3dimensional images that can detect abnormalities such as pulmonary embolism within the arteries in the lungs.

Venous thromboembolism treatment goals are to prevent clot from getting bigger, from breaking loose and traveling to the lungs and chances of another DVT. Medication includes anticoagulants, thrombolytics, inferior vena cava filters and superficial venous thrombosis. In rare cases, a surgical procedure is included to remove the clot. Thrombectomy - removal of clots in DVT patients and embolectomy – removal of blockages caused by the clots in in the lungs in PE patients.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Venous Thromboembolism treatment such as DD217, abelacimab, milvexian, EP-7041, and others. Key players involved in the development of therapies to treat venous thromboembolism are Anthos Therapeutics, Bristol-Myers Squibb, Daiichi Sankyo, and others. Five drugs are under Phase III clinical trials and five drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. In Sep 2022, Anthos Therapeutics received Fast Track Designation issued by the US FDA for abelacimab.

Report Highlights

Global Insight Service's, Venous Thromboembolism - Drug Pipeline Landscape, 2023 report provides an overview of the Venous Thromboembolism pipeline drugs. This report covers detailed insights on Venous Thromboembolism drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Venous Thromboembolism pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Venous Thromboembolism - Pipeline Drugs, 2023 - Coverage
2. Disease Overview - Venous Thromboembolism
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Venous Thromboembolism - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.4 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs - Phase III
5.1.1 DD217
5.1.2 Edoxaban
5.1.3 Isoquercetin
5.1.4 MAA868
5.1.5 Recombinant Non-Immunogenic Staphylokinase
5.2 Clinical Stage Drugs - Phase II
5.2.1 Fesomersen
5.2.2 Milvexian
5.2.3 Recombinant Human Prourokinase
5.2.4 S62798
5.2.5 SHR-2285
5.3 Clinical Stage Drugs - Phase I
5.3.1 EP-7041
5.3.2 GCC-4401C
5.3.3 Glenzocimab
5.3.4 ION547
5.3.5 ONO-7684
5.3.6 TF0023
5.3.7 TS23
5.3.8 VE-1902
5.4 Early-Stage Drugs - Preclinical
5.4.1 7300 Series
5.4.2 CM20161
5.4.3 Compoud-006
5.4.4 Compound-011
5.4.5 Dekaparin
5.4.6 GLY-102
5.4.7 GLY-103
5.4.8 MB104
5.4.9 SHX-020
5.5 Unknown Stage Drugs
5.5.1 BS-112
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Acticor Biotech
9.2 Anthos Therapeutics Inc
9.3 Bio-Synectics Inc
9.4 Bristol-Myers Squibb
9.5 CarboMimetics
9.6 Daiichi Sankyo Inc
9.7 eXIthera Pharmaceuticals
9.8 Glycan Therapeutics Inc
9.9 Guangzhou Dazhou Biomedical Technology Co Ltd
9.10 Ionis Pharmaceuticals Inc
9.11 Jiangsu Hengrui Medicine Co
9.12 Lee Pharma Ltd
9.13 Marizyme Inc
9.14 Ono Pharmaceutical Co Ltd
9.15 PharmaDiall Ltd
9.16 Protheragen Inc
9.17 Quercis Pharma
9.18 Servier
9.19 Supergene LLC
9.20 Tasly Pharmaceuticals
9.21 Techfields Pharma
9.22 Translational Sciences, Inc
9.23 Verseon Corp
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details - DD217/PharmaDiall Ltd
Table 2.2 Clinical Trial Details - Edoxaban/Daiichi Sankyo Inc
Table 2.3 Clinical Trial Details - Isoquercetin/Quercis Pharma
Table 2.4 Clinical Trial Details - MAA868/Anthos Therapeutics Inc
Table 2.5 Clinical Trial Details - Recombinant nonimmunogenic staphylokinase/Supergene LLC
Table 2.6 Clinical Trial Details - Fesomersen/Ionis Pharmaceuticals Inc
Table 2.7 Clinical Trial Details - Milvexian/Bristol-Myers Squibb
Table 2.8 Clinical Trial Details - Recombinant Human Prourokinase/Tasly Pharmaceuticals
Table 2.9 Clinical Trial Details - SHR-2285/Jiangsu Hengrui Medicine Co
Table 2.10 Clinical Trial Details - ION547/Ionis Pharmaceuticals Inc
Table 2.11 Clinical Trial Details - ONO-7684/Ono Pharmaceutical Co Ltd
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
List of Figures
Figure 1. 1 Number of Products under Development for Venous Thromboembolism , 2023
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Venous Thromboembolism , 2023
Figure 1. 3 Products by Top 5 Mechanism of Action for Venous Thromboembolism , 2023
Figure 1. 4 Products by Top 5 Molecule Type for Venous Thromboembolism , 2023
Figure 1. 5 Products by Top 5 Route of Administration for Venous Thromboembolism , 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings